The genetic-analysis company 23andMe has garnered a devoted following since its launch in 2006. Now the Food and Drug Administration has ordered the company to halt sales of its signature product, the Saliva Collection Kit and Personal Genome Service. Nita Farahany, professor of law, genomics and policy at Duke University, took the 23andMe test. She argues that the FDA is overreaching in their regulation of the company.
In an op-ed piece for our partner The New York Times, actress and director Angelina Jolie announced that she recently underwent a double mastectomy after learning that she is a carrier of the BRCA1 breast cancer gene and was at high risk for developing the disease. Is her choice one that is available to all women?
A tiny baby, born at 23 Weeks and 6 days -- roughly halfway to full term. And a whole universe of medical and moral questions.
Continuing a weekly series where we tackle thorny bioethical issues, Nita Farahany, Professor of Law and Philosophy and Professor of Genome Sciences & Policy at Duke University, discusses the limits of neuroenhancement.
This complete interview originally aired live on March 21, 2013 as part of a month-long series. An edited version was re-aired on August 2, 2013 as part of a special hour of Ask a Bioethicist in a best-of episode of The Brian Lehrer Show.